IRMA-International.org: Creator of Knowledge
Information Resources Management Association
Advancing the Concepts & Practices of Information Resources Management in Modern Organizations
navleft navright Research IRM Open Access IRMA Journals IRM Books Proceedings Membership

The IRMA Community

Calls for Papers
Online Symposium
Newsletters

Research IRM

Click a keyword to search titles using our InfoSci-OnDemand powered search:

Cannabinoid Efficacy for Developmental Epileptic Encephalopathy (DEE) Intractable Seizure Control: A Systematic Review of the Literature

Cannabinoid Efficacy for Developmental Epileptic Encephalopathy (DEE) Intractable Seizure Control: A Systematic Review of the Literature
View Sample PDF
Author(s): Courtney R. Acker (St. Mary Medical Center, USA)and Rana R. Zeine (Kean University, USA)
 Copyright: 2023
 Pages: 27
 Source title: Medical Cannabis and the Effects of Cannabinoids on Fighting Cancer, Multiple Sclerosis, Epilepsy, Parkinson's, and Other Neurodegenerative Diseases
Source Author(s)/Editor(s): Rana R. Zeine (Kean University, USA)and Brian W. Teasdale (Kean University, USA)
 DOI: 10.4018/978-1-6684-5652-1.ch003

Purchase

Abstract

Seizures in 20-30% of epileptics are resistant to treatment with anti-epileptic drugs (AED). This chapter evaluates studies on the efficacy of cannabinoids as adjunctive therapy for control of intractable seizures, with a focus on developmental epileptic encephalopathies (DEE). A systematic review conducted by literature search through PubMed, EBSCO, and ProQuest electronic databases identified 16 studies in the last seven years. Moderate- to low-certainty of evidence supports the benefits of cannabinoids in reducing seizure frequency, intensity, duration, and epileptics' overall condition in many types of intractable seizures. Studies used either synthetic cannabidiol (CBD), highly purified plant-derived CBD (Epidiolex®), or less pure cannabis plant-based CBD oils, and extended over months to two years. Drug interactions of ingested CBD with concomitant valproate and clobazam could be avoided with sublingual CBD. Five percent of patients became seizure free. Future studies are warranted to optimize the anti-seizure effects of emerging cannabinoid treatment strategies.

Related Content

Kamal Smimih, Bilal El-Mansoury, Chaima Azzouhri, Youssef Ait Hamdan, Fatima Ez-zahraa Saad, Merzouki Mohamed. © 2024. 19 pages.
Fatima Ez-Zahraa Saad, Kamal Smimih, Abdelali Bitar, Manal Khanouchi. © 2024. 12 pages.
Samira Boulbaroud, Hanane Khalki, Fatima Zahra Azzaoui. © 2024. 28 pages.
Bilal El-Mansoury, Kamal Smimih, Youssef Ait Hamdan, Ahmed Draoui, Samira Boulbaroud, Arumugam Radhakrishnan Jayakumar. © 2024. 23 pages.
Kamal Smimih, Chaima Azzouhri, Fatima Ez-Zahraa Saad, Youssef Ait Hamdan, Jawad Laadraoui, Nadia Zouhairi, Mohamed Merzouki. © 2024. 17 pages.
Himel Mondal, Shaikat Mondal. © 2024. 20 pages.
Hafida El Ghachi, Asmaa Haj-khlifa, Mjid Oukhrib, Lahcen Tamegart, Youssef Ait Hamdan, Abdelali Ben Maloui, Najib Kissani, Halima Gamrani. © 2024. 25 pages.
IRMA Offers Over 2,500 Full Text Open Access Research Papers for Free Download Click to Start Searching Free IRM Research!

IRMA Sponsors

Sponsor IGI Global

Sponsor eContentPro

Encyclopedia of Information Science and Technology, Fourth Edition
Body Bottom
About Us | Contact | Sitemap | Legal | Policies
Copyright ©2024, Information Resources Management Association. 701 East Chocolate Avenue, Hershey, PA 17033.